ArticleBrain and behavior2025
Long-Term Use of Benzodiazepines and Related Drugs in Persons With Major Depressive Disorder.
Article in Brain and behavior, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The Real-World Safety Profile of Temazepam: A 20-Year Pharmacovigilance Analysis Based on the Large-Scale FAERS Database.CNS neuroscience & therapeutics · 2026Article
- Neuroproteomic Profiling of the Anxiolytic Potential ofInternational journal of molecular sciences · 2026Article
- Long-Term Use of Benzodiazepines and Related Drugs in Persons With Major Depressive Disorder.Brain and behavior · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionBenzodiazepines and related drugs (BZDRs) may be prescribed to treat anxiety and insomnia in persons with depression. Although BZDRs are recommended for short-term use only, their use may be prolonged. Despite research on the use of BZDRs in depression, to our knowledge, long-term use and its predictors have not been previously studied. The aim of this study was to estimate the incidence of long-term BZDR use in persons with depression and to identify sociodemographic and clinical factors associated with prolonged use.
methodsData were extracted from Finnish nationwide registers. The study focused on persons with depression aged 16-65 years who initiated BZDR use between July 1, 2015 and June 30, 2018. Persons with a previous diagnosis of bipolar disorder, schizophrenia-spectrum disorder, or dementia, or those who did not have at least 180 days of follow-up, were excluded from the study. Sociodemographic and clinical factors associated with long-term (≥180 days) versus shorter use were compared with logistic regression. The final study sample included 11,303 BZDR initiators.
resultsA total of 849 (7.5%, CI 95% 7.0-8.0) BZDR initiators became long-term users. The mean age of long-term users was 39.8 years (SD 13.3), and more than half of them were females (58.9%). Factors associated with long-term BZDR use included age over 45 years (45-54: aOR 1.56, 95% CI 1.22-1.99, ≥55: 1.72, 1.32-2.25 compared to ≤24 years), male gender (1.49, 1.28-1.73), substance use disorder (excl. alcohol) (1.79, 1.27-2.29), use of opioid (1.75, 1.38-2.21) or quetiapine (1.65, 1.18-2.27), ≥3 antidepressants used in the previous year (1.63, 1.22-2.19), socioeconomic status other than employed, the use of antidepressants with hypnotic effects (1.25, 1.06-1.47) and anxiety disorder (1.16, 1.00-1.35).
conclusionsThis Finnish population-based cohort study identified sociodemographic and clinical factors that should be considered in the initiation and monitoring of BZDR treatment among persons with depression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.